ZA200109576B - Hydrochloride of fused-heterocycle compound. - Google Patents

Hydrochloride of fused-heterocycle compound. Download PDF

Info

Publication number: ZA200109576B
Authority: ZA; South Africa
Prior art keywords: compound; substance; composition; prophylaxis; medicament
Prior art date: 1999-05-24

Application number

ZA200109576A

Other languages

English (en)

Inventor

Takashi Fujita

Takashi Izumi

Toshihiko Fujiwara

Original Assignee

Sankyo Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-24

Filing date

2001-11-20

Publication date

2003-02-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15340495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200109576(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-11-20 Application filed by Sankyo Co filed Critical Sankyo Co

2003-02-20 Publication of ZA200109576B publication Critical patent/ZA200109576B/en

Links

VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title description 11
239000000203 mixture Substances 0.000 claims description 33
150000001875 compounds Chemical class 0.000 claims description 31
239000000126 substance Substances 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 13
238000000034 method Methods 0.000 claims description 13
208000002705 Glucose Intolerance Diseases 0.000 claims description 9
201000001421 hyperglycemia Diseases 0.000 claims description 9
201000009104 prediabetes syndrome Diseases 0.000 claims description 9
208000002249 Diabetes Complications Diseases 0.000 claims description 8
206010012655 Diabetic complications Diseases 0.000 claims description 8
206010022489 Insulin Resistance Diseases 0.000 claims description 8
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 5
238000011321 prophylaxis Methods 0.000 claims 7
238000011282 treatment Methods 0.000 claims 7
JXHFHOSKMYEEHT-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.O=C1CSC(=O)N1 JXHFHOSKMYEEHT-UHFFFAOYSA-N 0.000 claims 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
229940126062 Compound A Drugs 0.000 description 23
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 23
230000000694 effects Effects 0.000 description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
208000002177 Cataract Diseases 0.000 description 9
238000013519 translation Methods 0.000 description 9
206010012601 diabetes mellitus Diseases 0.000 description 8
238000009472 formulation Methods 0.000 description 8
208000031225 myocardial ischemia Diseases 0.000 description 8
208000004104 gestational diabetes Diseases 0.000 description 7
LKKAMJRUPIIUTC-UHFFFAOYSA-N 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride Chemical compound Cl.CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O LKKAMJRUPIIUTC-UHFFFAOYSA-N 0.000 description 6
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
208000031226 Hyperlipidaemia Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
-1 heterocyclic compound hydrochloride Chemical class 0.000 description 6
201000010065 polycystic ovary syndrome Diseases 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
102000004877 Insulin Human genes 0.000 description 5
108090001061 Insulin Proteins 0.000 description 5
206010029333 Neurosis Diseases 0.000 description 5
208000017442 Retinal disease Diseases 0.000 description 5
206010038923 Retinopathy Diseases 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 5
229920002678 cellulose Polymers 0.000 description 5
208000029078 coronary artery disease Diseases 0.000 description 5
239000008187 granular material Substances 0.000 description 5
229940125396 insulin Drugs 0.000 description 5
208000017169 kidney disease Diseases 0.000 description 5
208000015238 neurotic disease Diseases 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 description 5
208000002874 Acne Vulgaris Diseases 0.000 description 4
206010003210 Arteriosclerosis Diseases 0.000 description 4
201000001320 Atherosclerosis Diseases 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 4
206010006895 Cachexia Diseases 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
208000024172 Cardiovascular disease Diseases 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
208000004232 Enteritis Diseases 0.000 description 4
208000004930 Fatty Liver Diseases 0.000 description 4
201000005569 Gout Diseases 0.000 description 4
206010019708 Hepatic steatosis Diseases 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
208000008589 Obesity Diseases 0.000 description 4
208000001132 Osteoporosis Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
206010033645 Pancreatitis Diseases 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
206010037660 Pyrexia Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
206010042496 Sunburn Diseases 0.000 description 4
208000025865 Ulcer Diseases 0.000 description 4
206010000496 acne Diseases 0.000 description 4
208000026935 allergic disease Diseases 0.000 description 4
208000011775 arteriosclerosis disease Diseases 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
208000010668 atopic eczema Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
230000006931 brain damage Effects 0.000 description 4
231100000874 brain damage Toxicity 0.000 description 4
208000029028 brain injury Diseases 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
239000002775 capsule Substances 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
208000010706 fatty liver disease Diseases 0.000 description 4
150000002391 heterocyclic compounds Chemical class 0.000 description 4
208000027866 inflammatory disease Diseases 0.000 description 4
230000002757 inflammatory effect Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000003902 lesion Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
235000020824 obesity Nutrition 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
231100000240 steatosis hepatitis Toxicity 0.000 description 4
231100000397 ulcer Toxicity 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229920000881 Modified starch Polymers 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
241000700159 Rattus Species 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
210000001789 adipocyte Anatomy 0.000 description 3
230000003262 anti-osteoporosis Effects 0.000 description 3
230000009702 cancer cell proliferation Effects 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
230000002218 hypoglycaemic effect Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
150000002617 leukotrienes Chemical class 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
235000019426 modified starch Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 2
WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
102000016912 Aldehyde Reductase Human genes 0.000 description 2
108010053754 Aldehyde reductase Proteins 0.000 description 2
102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 2
108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical class [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
230000002213 calciumantagonistic effect Effects 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229950008138 carmellose Drugs 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000004957 immunoregulator effect Effects 0.000 description 2
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000012086 standard solution Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
XCLCHGDNINANNQ-UHFFFAOYSA-N 4-methoxy-2-n-methylbenzene-1,2-diamine Chemical compound CNC1=CC(OC)=CC=C1N XCLCHGDNINANNQ-UHFFFAOYSA-N 0.000 description 1
229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010010219 Compulsions Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
239000004287 Dehydroacetic acid Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
239000004373 Pullulan Substances 0.000 description 1
229920001218 Pullulan Polymers 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000003288 aldose reductase inhibitor Substances 0.000 description 1
WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
229960004217 benzyl alcohol Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125810 compound 20 Drugs 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
235000019258 dehydroacetic acid Nutrition 0.000 description 1
229940061632 dehydroacetic acid Drugs 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229940043264 dodecyl sulfate Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229960001381 glipizide Drugs 0.000 description 1
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229940126904 hypoglycaemic agent Drugs 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000008011 inorganic excipient Substances 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
RXAKVWMVWQZZGR-UHFFFAOYSA-N methyl 2-[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1CC1C(=O)NC(=O)S1 RXAKVWMVWQZZGR-UHFFFAOYSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008012 organic excipient Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
229940067107 phenylethyl alcohol Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000000047 product Substances 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
235000019423 pullulan Nutrition 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
229960004586 rosiglitazone Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
125000005624 silicic acid group Chemical class 0.000 description 1
NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000007614 solvation Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000012177 spermaceti Substances 0.000 description 1
229940084106 spermaceti Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000001467 thiazolidinediones Chemical class 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
229960005371 tolbutamide Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

ZA200109576A 1999-05-24 2001-11-20 Hydrochloride of fused-heterocycle compound. ZA200109576B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP14351399		1999-05-24

Publications (1)

Publication Number	Publication Date
ZA200109576B true ZA200109576B (en)	2003-02-20

Family

ID=15340495

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200109576A ZA200109576B (en)	1999-05-24	2001-11-20	Hydrochloride of fused-heterocycle compound.

Country Status (25)

Country	Link
US (1)	US6706746B2 (fr)
EP (1)	EP1180519B1 (fr)
KR (2)	KR100783348B1 (fr)
CN (1)	CN1156473C (fr)
AT (1)	ATE294799T1 (fr)
AU (1)	AU763731B2 (fr)
BR (1)	BR0010914A (fr)
CA (1)	CA2375017C (fr)
CZ (1)	CZ297927B6 (fr)
DE (1)	DE60019919T2 (fr)
DK (1)	DK1180519T3 (fr)
ES (1)	ES2240099T3 (fr)
HK (1)	HK1042087B (fr)
HU (1)	HU229340B1 (fr)
IL (1)	IL146568A0 (fr)
MX (1)	MXPA01012044A (fr)
NO (1)	NO321578B1 (fr)
NZ (1)	NZ515570A (fr)
PL (1)	PL209389B1 (fr)
PT (1)	PT1180519E (fr)
RU (1)	RU2214410C2 (fr)
TR (1)	TR200103353T2 (fr)
TW (1)	TWI284533B (fr)
WO (1)	WO2000071540A1 (fr)
ZA (1)	ZA200109576B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI284533B (en) *	1999-05-24	2007-08-01	Sankyo Co	Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
DE60123665T2 (de)	2000-12-26	2007-08-16	Sankyo Co., Ltd.	Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
US6756399B2 (en) *	2001-06-29	2004-06-29	The United States Of America As Represented By The Department Of Health And Human Services	Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
AU2003220855A1 (en) *	2002-04-01	2003-10-13	Sankyo Company, Limited	Medicinal antitumor composition
WO2004013109A1 (fr) *	2002-08-02	2004-02-12	Sankyo Company, Limited	Derive de resorcinol
US6794401B2 (en) *	2003-01-17	2004-09-21	Bexel Pharmaceuticals, Inc.	Amino acid phenoxy ethers
US7521465B2 (en) *	2003-01-17	2009-04-21	Bexel Pharmaceuticals, Inc.	Diphenyl ether derivatives
US7781464B2 (en) *	2003-01-17	2010-08-24	Bexel Pharmaceuticals, Inc.	Heterocyclic diphenyl ethers
WO2004106542A1 (fr)	2003-05-29	2004-12-09	Sankyo Company, Limited	Compose resistant a l'insuline et methode de criblage de celui-ci
US7087576B2 (en) *	2003-10-07	2006-08-08	Bexel Pharmaceuticals, Inc.	Dipeptide phenyl ethers
DE602004030470D1 (de) *	2003-10-24	2011-01-20	Santen Pharmaceutical Co Ltd	Therapeutisches mittel für keratokonjunktive erkrankungen
EP1566202A1 (fr) *	2004-02-23	2005-08-24	Sahltech I Göteborg AB	Utilisation d'agonistes de la resistine pour le traitement de l'arthrite rheumatoide
CA2560928A1 (fr) *	2004-03-29	2005-10-06	Sankyo Company Limited	Agent therapeutique pour diabete contenant un agent ameliorant la resistance a l'insuline
TW200608967A (en)	2004-07-29	2006-03-16	Sankyo Co	Pharmaceutical compositions containing with diabetic agent
TW200633720A (en) *	2004-12-13	2006-10-01	Sankyo Co	Medicinal composition for diabetic
TW200633702A (en) *	2004-12-15	2006-10-01	Sankyo Co	Medicinal composition containing fbpase inhibitor
TW200637856A (en) *	2005-01-24	2006-11-01	Sankyo Co	Process for producing thiazolidinedion compound and intermediate thereof
US20090227493A1 (en) *	2005-05-27	2009-09-10	Daiichi Sankyo Company, Limited	Combined drug for treating diabetes
US20080262054A1 (en) *	2005-07-08	2008-10-23	Takao Kawasaki	Pharmaceutical Composition Containing Thiazolidinedione Compound
TW200738266A (en) *	2005-09-29	2007-10-16	Sankyo Co	Pharmaceutical agent containing insulin resistance improving agent
JP5186217B2 (ja)	2005-11-28	2013-04-17	千寿製薬株式会社	Ｐｐａｒアゴニスト含有医薬
TW200838512A (en) *	2007-02-08	2008-10-01	Daiichi Sankyo Co Ltd	Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
CA2683089A1 (fr) *	2007-04-05	2008-10-23	Daiichi Sankyo Company, Limited	Derives de benzimidazole et derives de l'imidazopyridine a effet abaisseur de niveau glycemique
WO2008143254A1 (fr)	2007-05-21	2008-11-27	Senju Pharmaceutical Co., Ltd.	Produit pharmaceutique contenant un agoniste de pparδ
US8722710B2 (en)	2007-09-26	2014-05-13	Deuterx, Llc	Deuterium-enriched pioglitazone
CA2754446A1 (fr)	2009-03-05	2010-09-10	Daiichi Sankyo Company, Limited	Derive de pyridine
CA2941562C (fr)	2013-03-14	2021-09-21	Deuterx, Llc	2,4-thiazolidinediones enrichies en deuterium et methodes de traitement
WO2015109037A1 (fr)	2014-01-15	2015-07-23	Deuterx, Llc	Méthodes de traitement de troubles neurologiques, métaboliques et autres à l'aide de pioglitazone énantiopure enrichie en deutérium
US11767317B1 (en)	2020-06-30	2023-09-26	Poxel Sa	Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en)	2020-06-30	2022-05-03	Poxel Sa	Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5143930A (en) *	1990-02-07	1992-09-01	Sankyo Company, Limited	Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
CZ293016B6 (cs)	1995-06-01	2004-01-14	Sankyo Company Limited	Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
HUP9601808A3 (en)	1995-07-03	2000-06-28	Sankyo Co	Treatment of arteriosclerosis and xanthoma
TWI284533B (en) *	1999-05-24	2007-08-01	Sankyo Co	Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
KR20020015383A (ko) *	1999-07-19	2002-02-27	가와무라 요시부미	암의 예방제 및 치료제

2000
- 2000-05-23 TW TW089109943A patent/TWI284533B/zh not_active IP Right Cessation
- 2000-05-24 MX MXPA01012044A patent/MXPA01012044A/es active IP Right Grant
- 2000-05-24 TR TR2001/03353T patent/TR200103353T2/xx unknown
- 2000-05-24 AT AT00931547T patent/ATE294799T1/de active
- 2000-05-24 EP EP00931547A patent/EP1180519B1/fr not_active Expired - Lifetime
- 2000-05-24 WO PCT/JP2000/003325 patent/WO2000071540A1/fr not_active Ceased
- 2000-05-24 CA CA002375017A patent/CA2375017C/fr not_active Expired - Fee Related
- 2000-05-24 KR KR1020077003629A patent/KR100783348B1/ko not_active Expired - Fee Related
- 2000-05-24 DK DK00931547T patent/DK1180519T3/da active
- 2000-05-24 CN CNB008107831A patent/CN1156473C/zh not_active Expired - Fee Related
- 2000-05-24 HU HU0201334A patent/HU229340B1/hu not_active IP Right Cessation
- 2000-05-24 KR KR1020017014773A patent/KR100748053B1/ko not_active Expired - Fee Related
- 2000-05-24 IL IL14656800A patent/IL146568A0/xx not_active IP Right Cessation
- 2000-05-24 ES ES00931547T patent/ES2240099T3/es not_active Expired - Lifetime
- 2000-05-24 PL PL351650A patent/PL209389B1/pl not_active IP Right Cessation
- 2000-05-24 DE DE60019919T patent/DE60019919T2/de not_active Expired - Lifetime
- 2000-05-24 AU AU49487/00A patent/AU763731B2/en not_active Ceased
- 2000-05-24 PT PT00931547T patent/PT1180519E/pt unknown
- 2000-05-24 BR BR0010914-2A patent/BR0010914A/pt not_active Application Discontinuation
- 2000-05-24 HK HK02103877.0A patent/HK1042087B/en not_active IP Right Cessation
- 2000-05-24 NZ NZ515570A patent/NZ515570A/en not_active IP Right Cessation
- 2000-05-24 RU RU2001131722/04A patent/RU2214410C2/ru not_active IP Right Cessation
- 2000-05-24 CZ CZ20014182A patent/CZ297927B6/cs not_active IP Right Cessation
2001
- 2001-11-20 ZA ZA200109576A patent/ZA200109576B/en unknown
- 2001-11-21 US US09/991,100 patent/US6706746B2/en not_active Expired - Fee Related
- 2001-11-23 NO NO20015712A patent/NO321578B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
PL209389B1 (pl)	2011-08-31
TWI284533B (en)	2007-08-01
DK1180519T3 (da)	2005-06-13
CN1364168A (zh)	2002-08-14
DE60019919T2 (de)	2006-02-16
US20020111373A1 (en)	2002-08-15
CZ20014182A3 (cs)	2002-04-17
KR100748053B1 (ko)	2007-08-09
HUP0201334A2 (en)	2002-10-28
KR20070034112A (ko)	2007-03-27
DE60019919D1 (de)	2005-06-09
PL351650A1 (en)	2003-05-19
CA2375017C (fr)	2009-05-19
PT1180519E (pt)	2005-06-30
NO321578B1 (no)	2006-06-06
CA2375017A1 (fr)	2000-11-30
HK1042087A1 (en)	2002-08-02
BR0010914A (pt)	2002-02-19
MXPA01012044A (es)	2002-05-06
RU2214410C2 (ru)	2003-10-20
KR20010113972A (ko)	2001-12-28
WO2000071540A1 (fr)	2000-11-30
ATE294799T1 (de)	2005-05-15
HK1042087B (en)	2005-09-09
NO20015712L (no)	2001-12-20
EP1180519A4 (fr)	2002-07-10
CN1156473C (zh)	2004-07-07
HUP0201334A3 (en)	2002-11-28
NO20015712D0 (no)	2001-11-23
CZ297927B6 (cs)	2007-05-02
TR200103353T2 (tr)	2002-04-22
AU4948700A (en)	2000-12-12
EP1180519A1 (fr)	2002-02-20
IL146568A0 (en)	2002-07-25
HU229340B1 (en)	2013-11-28
NZ515570A (en)	2003-11-28
EP1180519B1 (fr)	2005-05-04
KR100783348B1 (ko)	2007-12-07
AU763731B2 (en)	2003-07-31
US6706746B2 (en)	2004-03-16
ES2240099T3 (es)	2005-10-16

Publication	Publication Date	Title
EP1180519B1 (fr)	2005-05-04	Chlorhydrate de compose heterocyclique fusionne
US10150779B2 (en)	2018-12-11	Aldose reductase inhibitors and methods of use thereof
CN103052637A (zh)	2013-04-17	醛糖还原酶抑制剂及其用途
JP2001039976A (ja)	2001-02-13	縮合複素環化合物の塩酸塩
JP2002220336A (ja)	2002-08-09	縮合複素環化合物の塩酸塩を含有する糖尿病の予防薬、治療薬
US6214842B1 (en)	2001-04-10	Amino-thiazolidinediones useful in the treatment of insulin resistance and hyperglycemia
JPH01228914A (ja)	1989-09-12	アルドースリダクターゼ阻害剤
KR20070027483A (ko)	2007-03-09	로시글리타존 말레이트의 다형을 제조하는 방법
JP2005320250A (ja)	2005-11-17	ビスラクトン誘導体及びその医薬組成物としての使用
CA2379662A1 (fr)	2001-01-25	Agents preventifs et therapeutiques du cancer
WO1995007898A1 (fr)	1995-03-23	Compose d'acide succinamique, procede pour sa fabrication, et son utilisation
HK40105726A (en)	2024-08-23	4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
HK40044237A (en)	2021-09-30	4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
HK40044237B (en)	2024-05-10	4-oxo-3,4-dihydrothieno[3,4-d]pyridazine compounds as aldose reductase inhibitors and methods of use thereof
CN112538086A (zh)	2021-03-23	杂卓并三唑环同吲哚羧酸拼合物及其盐、其制备方法及医药用途
HK1259379B (en)	2021-04-23	Aldose reductase inhibitors and methods of use thereof
JP2000191588A (ja)	2000-07-11	シクロ化合物及びその医薬用途